tetano
Editor, Senior Moderator
J Infect Public Health
. 2021 May 31;14(8):1021-1027.
doi: 10.1016/j.jiph.2021.05.015. Online ahead of print.
Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes
Abeer Al-Baadani[SUP] 1 [/SUP], Nazik Eltayeb[SUP] 1 [/SUP], Eid Alsufyani[SUP] 1 [/SUP], Salma Albahrani[SUP] 2 [/SUP], Shareefah Basheri[SUP] 3 [/SUP], Hawra Albayat[SUP] 4 [/SUP], Enas Batubara[SUP] 3 [/SUP], Sulafa Ballool[SUP] 4 [/SUP], Ayed Al Assiri[SUP] 4 [/SUP], Fahad Faqihi[SUP] 4 [/SUP], Ali B Musa[SUP] 5 [/SUP], Asirvatham A Robert[SUP] 6 [/SUP], Nisreen Alsherbeeni[SUP] 1 [/SUP], Fatehi Elzein[SUP] 7 [/SUP]
Affiliations
Abstract
Background: SARS-CoV-2 is associated with a severe inflammatory response contributing to respiratory and systemic manifestations, morbidity, and mortality in patients with coronavirus disease 2019 (COVID-19).
Methods: Tocilizumab (TCZ) efficacy on mortality and length of hospital stay was retrospectively evaluated in patients who received TCZ and compared with that in controls with a similar severity of COVID-19. The primary endpoint was survival probability on day 28. The secondary endpoints included survival at day 14 and length of hospital stay.
Results: Of the 148 patients included in the study, 62 received TCZ and standard of care, whereas 86 served as a control group and received only standard of care. The two groups were similar, although TCZ-treated patients were more likely to exhibit hypertension (46.7% vs. 29.8%), chronic kidney disease (14.5% vs. 1.1%), and high Charlson score (1.18 vs. 1.00; p = 0.006) and less likely to receive corticosteroid treatment (48.5% vs. 93.0%). TCZ was associated with lower mortality on both day 28 (16.1% vs. 37.2%, p = 0.004) and day 14 (9.7% vs. 24.4%, p = 0.022). The hospital stay was longer in the TCZ-treated than in the control group (15.6 ± 7.59 vs.17.7 ± 7.8 days, p = 0.103). Ten patients (16.0%) in the TCZ-treated group developed infections.
Conclusion: TCZ was associated with a lower likelihood of death despite resulting in higher infection rates and a non-significant longer hospital stay.
Keywords: COVID-19; Hospital stay; Interleukin-6; SARS-CoV2; Survival; Tocilizumab.
. 2021 May 31;14(8):1021-1027.
doi: 10.1016/j.jiph.2021.05.015. Online ahead of print.
Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes
Abeer Al-Baadani[SUP] 1 [/SUP], Nazik Eltayeb[SUP] 1 [/SUP], Eid Alsufyani[SUP] 1 [/SUP], Salma Albahrani[SUP] 2 [/SUP], Shareefah Basheri[SUP] 3 [/SUP], Hawra Albayat[SUP] 4 [/SUP], Enas Batubara[SUP] 3 [/SUP], Sulafa Ballool[SUP] 4 [/SUP], Ayed Al Assiri[SUP] 4 [/SUP], Fahad Faqihi[SUP] 4 [/SUP], Ali B Musa[SUP] 5 [/SUP], Asirvatham A Robert[SUP] 6 [/SUP], Nisreen Alsherbeeni[SUP] 1 [/SUP], Fatehi Elzein[SUP] 7 [/SUP]
Affiliations
- PMID: 34153727
- DOI: 10.1016/j.jiph.2021.05.015
Abstract
Background: SARS-CoV-2 is associated with a severe inflammatory response contributing to respiratory and systemic manifestations, morbidity, and mortality in patients with coronavirus disease 2019 (COVID-19).
Methods: Tocilizumab (TCZ) efficacy on mortality and length of hospital stay was retrospectively evaluated in patients who received TCZ and compared with that in controls with a similar severity of COVID-19. The primary endpoint was survival probability on day 28. The secondary endpoints included survival at day 14 and length of hospital stay.
Results: Of the 148 patients included in the study, 62 received TCZ and standard of care, whereas 86 served as a control group and received only standard of care. The two groups were similar, although TCZ-treated patients were more likely to exhibit hypertension (46.7% vs. 29.8%), chronic kidney disease (14.5% vs. 1.1%), and high Charlson score (1.18 vs. 1.00; p = 0.006) and less likely to receive corticosteroid treatment (48.5% vs. 93.0%). TCZ was associated with lower mortality on both day 28 (16.1% vs. 37.2%, p = 0.004) and day 14 (9.7% vs. 24.4%, p = 0.022). The hospital stay was longer in the TCZ-treated than in the control group (15.6 ± 7.59 vs.17.7 ± 7.8 days, p = 0.103). Ten patients (16.0%) in the TCZ-treated group developed infections.
Conclusion: TCZ was associated with a lower likelihood of death despite resulting in higher infection rates and a non-significant longer hospital stay.
Keywords: COVID-19; Hospital stay; Interleukin-6; SARS-CoV2; Survival; Tocilizumab.